Are selective estrogen receptor modulators (SERMs) a therapeutic option for HPV-associated cervical lesions and cancers?
This Commentary highlights the article by Spurgeon et al which evaluates oral SERM raloxifene as a potential therapeutic agent for HPV-associated cancer.